Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy.

JAMA - 3 Apr 2002

Higashi Mitchell K, Veenstra David L, Kondo L Midori, Wittkowsky Ann K, Srinouanprachanh Sengkeo L, Farin Fred M, Rettie Allan E

Abstract excerpt

CONTEXT: Warfarin is a commonly used anticoagulant that requires careful clinical management to balance the risks of overanticoagulation and bleeding with those of underanticoagulation and clotting. The principal enzyme involved in warfarin metabolism is CYP2C9, and 2 relatively common variant fo...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anticoagulants
Share to Blood Coagulation
Share to Cytochrome P-450 CYP2C9

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hemorrhage

Share to International Normalized Ratio

Share to Steroid 16-alpha-Hydroxylase

Share to Steroid Hydroxylases

Share to Warfarin

Source

Identifiers

PMID: 11926893
DOI: 10.1001/jama.287.13.1690

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-11926893-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy.PMID 11926893Read ↗

Effect of polymorphisms in the cytochrome P450 CYP2C9 gene on warfarin anticoagulation.Semantic proximity Read ↗

Several-fold increase in risk of overanticoagulation by CYP2C9 mutations.Semantic proximity Read ↗

Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment.Semantic proximity Read ↗

Increased frequency of CYP2C9 variant alleles and homozygous VKORC1*2B carriers in warfarin-treated patients with excessive INR response.Semantic proximity Read ↗

The influence of VKORC1 and CYP2C9 gene sequence variants on the stability of maintenance phase warfarin treatment.Semantic proximity Read ↗

CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis.Semantic proximity Read ↗

The risk of bleeding complications in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon.Semantic proximity Read ↗

The bleeding risk during warfarin therapy is associated with the number of variant alleles of CYP2C9 and VKORC1 genes.Semantic proximity Read ↗

CYP2C9 genotypes and the quality of anticoagulation control with warfarin therapy among Brazilian patients.Semantic proximity Read ↗

Genotype and risk of major bleeding during warfarin treatment.Semantic proximity Read ↗

Effects of cytochrome P450 2C9 polymorphisms on phenprocoumon anticoagulation status.Semantic proximity Read ↗

Influence of CYP2C9 and VKORC1 genotypes on the risk of hemorrhagic complications in warfarin-treated patients: a systematic review and meta-analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.